Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trialsAlexander Drilon, Robert C. Doebele, Salvatore Siena et al.|The Lancet Oncology|2019Cited by 537
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)Young Kwang Chae, Francis J. Giles, Ayush Arya et al.|Journal for ImmunoTherapy of Cancer|2018Cited by 468
A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine TumorsSandip Pravin Patel, Razelle Kurzrock, Megan Othus et al.|Clinical Cancer Research|2020Cited by 326
Repurposing metformin for cancer treatment: current clinical studiesYoung Kwang Chae, Francis J. Giles|Oncotarget|2016Cited by 313
Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC)Young Kwang Chae, Marcelo Cruz, Sangmin Chang et al.|Scientific Reports|2018Cited by 258